A carregar...
What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia (CLL), with an incidence rate between 4 and 6 cases per 100,000 persons per year, is considered the most prevalent leukemia in the western world. Chemoimmunotherapy (such as fludarabine, cyclophosphamide, and rituximab), bendamustine plus rituximab, and, more recently, n...
Na minha lista:
| Publicado no: | Cell Transplant |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784498/ https://ncbi.nlm.nih.gov/pubmed/32907382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689720950209 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|